Novo Nordisk's liraglutide beats standard therapy in study

06/8/2009 | Reuters

Novo Nordisk's diabetes drug liraglutide beat a commonly used rival, Sanofi-Aventis' glimepiride, in controlling blood sugar and caused some patients to lose weight, according to a two-year trial. The study showed a 1.1% decline in A1C blood-sugar levels in patients taking liraglutide compared with a 0.6% reduction in those taking glimepiride.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Associate Director, Regulatory Affairs - Promotional Review
Novo Nordisk
Princeton, NJ